Biomarkers for antigen immunotherapy in allergy and type 1 diabetes

Clinical Immunology

Volumn 161, Issue 1, 2015, Pages 44-50

  Odegard, Jared M ^a   Nepom, Gerald T ^a   Wambre, Erik ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Allergy; Biomarkers; Immunotherapy; Pathogenesis; Type 1 diabetes

Indexed keywords

ALLERGEN; AMINE OXIDASE (COPPER CONTAINING); ANTIGEN; AUTOANTIGEN; BIOLOGICAL MARKER; CD203C ANTIGEN; CD63 ANTIGEN; COMPLEMENT COMPONENT C1; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOLOGIC AGENT; INSULIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OSTEOPONTIN; STABILIN 1; THYMIC STROMAL LYMPHOPOIETIN; TRYPTASE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ALLERGIC RHINITIS; ALLERGY; ANALYTIC METHOD; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BASOPHIL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DNA SYNTHESIS; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHIL COUNT; FLOW CYTOMETRY; GRASS POLLEN; HISTAMINE RELEASE; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MASS SPECTROMETRY; MEDIATOR RELEASE; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT OUTCOME; AUTOIMMUNE DISEASES; BIOLOGICAL MODEL; DIABETES MELLITUS, TYPE 1; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES; T LYMPHOCYTE;

ANTIGENS; AUTOIMMUNE DISEASES; BIOMARKERS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPERSENSITIVITY; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 84949538187     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.05.023     Document Type: Review

References (40)

1. Ciprandi G., Alesina R., De Amici M. Serum specific IgE: biomarker for specific immunotherapy responsiveness?. Allergol. Immunopathol. (Madr.) 2014, 42:369-371.
2. Özdemir S.K., Güloğlu D., Sin B.A., Elhan A.H., Ikinciogullari A., Misirligil Z. Reliability of basophil activation test using CD203c expression in diagnosis of pollen allergy. Am. J. Rhinol. Allergy 2011, 25:e225-e231.
3. Santos A.F., Douiri A., Becares N., Wu S.Y., Stephens A., Radulovic S., Chan S.M., Fox A.T., Du T.G., Turcanu V., Lack G. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. J. Allergy Clin. Immunol. 2014, 134:645-652.
4. Patil S.U., Shreffler W.G. Immunology in the Clinic Review Series; focus on allergies: basophils as biomarkers for assessing immune modulation. Clin. Exp. Immunol. 2012, 167:59-66.
5. Nouri-Aria K.T., Wachholz P.A., Francis J.N., Jacobson M.R., Walker S.M., Wilcock L.K., Staple S.Q., Aalberse R.C., Till S.J., Durham S.R. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 2004, 172:3252-3259.
6. Bodtger U., Ejrnaes A.M., Hummelshoj L., Jacobi H.H., Poulsen L.K., Svenson M. Is immunotherapy-induced birch-pollen-specific IgG4 a marker for decreased allergen-specific sensitivity?. Int. Arch. Allergy Immunol. 2005, 136:340-346.
7. Nagao M., Hiraguchi Y., Hosoki K., Tokuda R., Usui T., Masuda S., Yamaguchi M., Fujisawa T. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Int. Arch. Allergy Immunol. 2008, 146(Suppl. 1):47-53.
8. Shamji M.H., Layhadi J.A., Scadding G.W., Cheung D.K., Calderon M.A., Turka L.A., Phippard D., Durham S.R. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. J. Allergy Clin. Immunol. 2014, 6749:1477-1478.
9. Di Lorenzo G., Mansueto P., Pacor M.L., Martinelli N., Rizzo M., Ditta V., Leto-Barone M.S., D'Alcamo A., Politi D., Pepe I., Rotolo G., Di Fede G., Caruso C., Rini G.B., Corrocher R. Clinical importance of eosinophil count in nasal fluid in patients with allergic and non-allergic rhinitis. Int. J. Immunopathol. Pharmacol. 2009, 22:1077-1087.
10. Busse W., Spector S., Rosen K., Wang Y., Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J. Allergy Clin. Immunol. 2013, 132:485-486.
11. Scadding G.W., Calderon M.A., Bellido V., Koed G.K., Nielsen N.C., Lund K., Togias A., Phippard D., Turka L.A., Hansel T.T., Durham S.R., Wurtzen P.A. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J. Immunol. Methods 2012, 384:25-32.
12. Konno S., Golden D.B., Schroeder J., Hamilton R.G., Lichtenstein L.M., Huang S.K. Level of osteopontin is increased after bee venom immunotherapy. J. Allergy Clin. Immunol. 2005, 115:1317-1318.
13. Zimmer A., Bouley J., Le Mignon M., Pliquet E., Horiot S., Turfkruyer M., Baron-Bodo V., Horak F., Nony E., Louise A., Moussu H., Mascarell L., Moingeon P. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. J. Allergy Clin. Immunol. 2012, 129:1020-1030.
14. Lao-Araya M., Steveling E., Scadding G.W., Durham S.R., Shamji M.H. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J. Allergy Clin. Immunol. 2014, 134:1193-1195.
15. Kwok W.W., Roti M., DeLong J.H., Tan V., Wambre E., James E.A., Robinson D. Direct ex vivo analysis of allergen-specific CD4+ T cells. J. Allergy Clin. Immunol. 2010, 125:1407-1409.
16. Wambre E., James E.A., Kwok W.W. Characterization of CD4+ T cell subsets in allergy. Curr. Opin. Immunol. 2012, 24:700-706.
17. Wambre E., DeLong J.H., James E.A., Torres-Chinn N., Pfutzner W., Mobs C., Durham S.R., Till S.J., Robinson D., Kwok W.W. Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner. J. Allergy Clin. Immunol. 2014, 133:872-879.
18. Wambre E., DeLong J.H., James E.A., Lafond R.E., Robinson D., Kwok W.W. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J. Allergy Clin. Immunol. 2012, 129:544-551.
19. Gilles S., Traidl-Hoffmann C. CD27 expression on allergen-specific T cells: a new surrogate for successful allergen-specific immunotherapy?. J. Allergy Clin. Immunol. 2012, 129:552-554.
20. Wambre E., DeLong J.H., James E.A., Robinson D.M., Kwok W.W. TH2A cells as a unique TH2 cell subset in allergic individuals: steps toward a T cell biomarker for allergy. J. Allergy Clin. Immunol. 2012, 129:AB129.
21. Harrison L.C., Honeyman M.C., Steele C.E., Stone N.L., Sarugeri E., Bonifacio E., Couper J.J., Colman P.G. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27:2348-2355.
22. Orban T., Farkas K., Jalahej H., Kis J., Treszl A., Falk B., Reijonen H., Wolfsdorf J., Ricker A., Matthews J.B., Tchao N., Sayre P., Bianchine P. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J. Autoimmun. 2010, 34:408-415.
23. Greenbaum C.J., McCulloch-Olson M., Chiu H.K., Palmer J.P., Brooks-Worrell B. Parenteral insulin suppresses T cell proliferation to islet antigens. Pediatr. Diabetes 2011, 12:150-155.
24. Axelsson S., Cheramy M., Akerman L., Pihl M., Ludvigsson J., Casas R. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care 2013, 36:3418-3424.
25. Monti P., Scirpoli M., Rigamonti A., Mayr A., Jaeger A., Bonfanti R., Chiumello G., Ziegler A.G., Bonifacio E. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J. Immunol. 2007, 179:5785-5792.
26. Fourlanos S., Perry C., Gellert S.A., Martinuzzi E., Mallone R., Butler J., Colman P.G., Harrison L.C. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011, 60:1237-1245.
27. Thrower S.L., James L., Hall W., Green K.M., Arif S., Allen J.S., Van-Krinks C., Lozanoska-Ochser B., Marquesini L., Brown S., Wong F.S., Dayan C.M., Peakman M. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin. Exp. Immunol. 2009, 155:156-165.
28. Hjorth M., Axelsson S., Ryden A., Faresjo M., Ludvigsson J., Casas R. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. Clin. Immunol. 2011, 138:117-126.
29. Axelsson S., Chéramy M., Hjorth M., Pihl M., Akerman L., Martinuzzi E., Mallone R., Ludvigsson J., Casas R. Long-lasting immune responses 4years after GAD-alum treatment in children with type 1 diabetes. PLoS One 2011, 6:e29008.
30. Pihl M., Akerman L., Axelsson S., Chéramy M., Hjorth M., Mallone R., Ludvigsson J., Casas R. Regulatory T cell phenotype and function 4years after GAD-alum treatment in children with type 1 diabetes. Clin. Exp. Immunol. 2013, 172:394-402.
31. Reijonen H., Kwok W.W., Nepom G.T. Detection of CD4+ autoreactive T cells in T1D using HLA class II tetramers. Ann. N. Y. Acad. Sci. 2003, 1005:82-87.
32. Pinkse G.G., Tysma O.H., Bergen C.A., Kester M.G., Ossendorp F., van Veelen P.A., Keymeulen B., Pipeleers D., Drijfhout J.W., Roep B.O. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18425-18430.
33. Nepom G.T. MHC class II tetramers. J. Immunol. 2012, 188:2477-2482.
34. Velthuis J.H., Unger W.W., Abreu J.R., Duinkerken G., Franken K., Peakman M., Bakker A.H., Reker-Hadrup S., Keymeulen B., Drijfhout J.W., Schumacher T.N., Roep B.O. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010, 59:1721-1730.
35. Roep B.O., Solvason N., Gottlieb P.A., Abreu J.R., Harrison L.C., Eisenbarth G.S., Yu L., Leviten M., Hagopian W.A., Buse J.B., von Herrath M., Quan J., King R.S., Robinson W.H., Utz P.J., Garren H., Steinman L. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes. Sci. Transl. Med. 2013, 5:191ra82.
36. Scriba T.J., Purbhoo M., Day C.L., Robinson N., Fidler S., Fox J., Weber J.N., Klenerman P., Sewell A.K., Phillips R.E. Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J. Immunol. 2005, 175:6334-6343.
37. Wolfl M., Kuball J., Ho W.Y., Nguyen H., Manley T.J., Bleakley M., Greenberg P.D. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110:201-210.
38. Bacher P., Schink C., Teutschbein J., Kniemeyer O., Assenmacher M., Brakhage A.A., Scheffold A. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J. Immunol. 2013, 190:3967-3976.
39. Huurman V.A., van der Meide P.E., Duinkerken G., Willemen S., Cohen I.R., Elias D., Roep B.O. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin. Exp. Immunol. 2008, 152:488-497.
40. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358:1749-1753.